Nektar raises new $125m debt to clean out old debt and focus on asset progress
This article was originally published in Scrip
Executive Summary
Nektar Therapeutics closed the private placement of $125 million in senior secured notes on 11 July, which will help the San Francisco-based company pay off a debt due in September and hold firm on its commitment to advance one preclinical asset per year into the clinic.